Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 8

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 8
---
, as applicable, depends
and will depend upon, among other things, these products and product candidates gaining and maintaining acceptance by physicians, patients,
third-party payors and other members of the medical community as efficacious and cost-effective alternatives to competing products and
treatments. If any of our products or product candidates do not achieve and maintain an adequate level of acceptance, we may not generate
material sales of that product or product candidate or be able to successfully commercialize it. The degree of market acceptance of our
products and product candidates, if authorized for sale or certified, will depend on a number of factors, including:

  our ability to provide acceptable evidence of safety and efficacy;  

  the prevalence and severity of any side effects;  

  publicity concerning our products and product candidates or competing products and treatments;  

  availability, relative cost and relative efficacy of alternative and competing treatments;  

  the ability to offer our products for sale at competitive prices;  

  the relative convenience and ease of administration of our products and product candidates;  

  the willingness of the target patient population to try new products and product candidates and the willingness of physicians to prescribe these products and product candidates;  

  the strength of marketing and distribution support; and  

  the sufficiency of coverage or reimbursement by third parties.  

If our Alpha DaRT technology
or any of our other future products or product candidates, if authorized or certified, do not become widely accepted by potential customers,
physicians, patients, third-party payors and other members of the medical community, such a lack of acceptance could have a material adverse
effect on our business, financial condition and results of operations.

If product liability lawsuits are brought
against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.

We face an inherent risk of
product liability as a result of the planned clinical testing of our product candidates and will face an even greater risk if we commercialize
any products. For example, we may be sued if our Alpha DaRT technology or any future products or product candidates we develop, cause
or are perceived to cause injury or are found to be otherwise unsuitable during clinical trials, manufacturing, marketing or sale. Any
such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent
in the product (which may include inherent dangers in the use of radioactive materials), negligence, strict liability or a breach of warranties.
Claims could also be asserted under state consumer protection acts.